Exogene

Curated by Signal

Developer of AI-powered T-cell-receptor-based immunotherapies for cancer treatment

Overview

Developer of AI-powered T-cell-receptor-based immunotherapies for cancer treatment. The company's proprietary platform combines artificial intelligence with genomics, structural biology, and biophysics to optimize the development of cancer immunotherapies. It helps to reduce the side effects of higher dosing.

Key facts

Founded: 2019
Headquarters: London, United Kingdom
Stage: Sign up to view
Industry: Life Sciences Technology

Business model

2 products and services: Sign up to view

Contact

Primary office: Sign up to view
Email: Sign up to view

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Life Sciences Technology companies

Pulmolink
Develops a range of respiratory testing and monitoring devices
Life Sciences TechnologyKent, United Kingdom
Tarilian Laser Technologies
Optical sensor based cuff less, continuous, non-invasive blood pressure monitor
Life Sciences TechnologyHertford, United Kingdom
VANA Health
Provider of supplements based on AI health tracking application
Life Sciences TechnologyLondon, United Kingdom

About Exogene

What does Exogene do?

Developer of AI-powered T-cell-receptor-based immunotherapies for cancer treatment.

Where is Exogene headquartered?

Exogene is headquartered in London, United Kingdom.

When was Exogene founded?

Exogene was founded in 2019.

Which sector is Exogene in?

Exogene operates in Life Sciences Technology.

Who are Exogene's competitors?

Companies similar to Exogene include Pulmolink, Tarilian Laser Technologies, and VANA Health.